Press Releases 2019

AMF concludes its review of the refinancing transactions completed by Liminal in April 2019

The AMF has determined that no violation or breach of securities regulation occurred in connection with the refinancing transactions completed by the Company in April 2019.

Liminal BioSciences to present at Piper Jaffray healthcare conference

The management team will provide a business overview and update at the Piper Jaffray 31st Annual Healthcare Conference at 08:10 ET on Wednesday, December 4, 2019 in New York, USA

Liminal BioSciences announces closing of divestiture of bioseparations division to KKR

LMNL announced today it has closed on the previously announced divestment of its Isle of Man-based bioseparations business operated through its subsidiary Prometic Bioseparations Ltd. to KKR & Co.

LMNL presents new preclinical data on PBI-4050 and its effect on angio-proliferative pulmonary arterial hypertension

LMNL to present two scientific posters with new preclinical data for PBI-4050 and the treatment of pulmonary arterial hypertension (“PAH”) at the American Heart Association conference.

Liminal BioSciences to present at the Jefferies 2019 London healthcare conference

Members of the management team will provide a business overview and update at the Jefferies 2019 London Healthcare Conference at 18:00 GMT on Wednesday, November 20, 2019 in London, UK.

Liminal BioSciences announces effectiveness of registration statement on form F-10 and filing of prospectus supplement

LMNL announced today that its registration statement on Form F-10 (the “Registration Statement”), which was filed with the United States Securities and Exchange Commission (the “SEC”) on November 12

Liminal BioSciences to present at Stifel healthcare conference

LMNL management team will provide a business overview and update at the Stifel Healthcare Conference at 14:25 ET on Tuesday, November 19, 2019 in New York, USA.

Liminal BioSciences to commence trading common shares on NASDAQ

Trading is expected to commence on NASDAQ on Monday, November 18, 2019, under the ticker symbol ‘LMNL’.

Liminal BioSciences announces key appointment to its leadership team

LMNL announced today the addition of Moira Daniels as the new Head of Regulatory Affairs and Quality Assurance, to its senior leadership team.

Liminal BioSciences presents new preclinical data on PBI-4050 and NASH candidate PBI-4547

Liminal BioSciences reports its 2019 third quarter financial results and business highlights

Liminal BioSciences to report Q3 2019 results and hold conference call

Liminal BioSciences presents new preclinical data at ASN kidney week 2019

LMNL collaborators presented new preclinical findings on a novel therapeutic approach to the treatment of inflammatory and fibrosis-related kidney diseases at the American Society of Nephrology’s

Liminal BioSciences to divest bioseparations division to KKR

LMNL announced today the signature of a binding share purchase agreement for the divestment of its Isle of Man-based bioseparations business operated through its subsidiary Prometic Bioseparations Ltd

Liminal BioSciences announces upcoming presentations with new data on Pulmonary Arterial Hypertension at the 2019 AHA meeting

Liminal BioSciences announces upcoming presentations new data on Pulmonary Arterial Hypertension at the 2019 AHA meeting

Liminal BioSciences announces upcoming presentations at The Liver Meeting 2019

Liminal Bio anannounced the presentation of three abstracts related to the Company’s pre-clinical development activities for the treatment of liver diseases at the The Liver Meeting 2019 of the AASLD

Liminal BioSciences announces upcoming presentations at ASN kidney week 2019

Liminal BioSciences and its’ collaborators will present preclinical findings on a novel therapeutic approach to the treatment of inflammatory and fibrosis-related kidney diseases at ASN Kidney Week.

Liminal BioSciences to present at H.C. Wainwright & Co. 3rd annual NASH investor conference

Liminal BioSciences announced today, that members of the management team will provide a presentation on PBI-4547 as a potential treatment for NASH

Prometic shareholders approve name change to Liminal BioSciences Inc.

Shareholders representing approximatively 87% of votes cast approved a special resolution authorizing the Company to amend its articles to change its name to Liminal BioSciences Inc.